Show simple item record

dc.contributor.authorSavinkina, Alexandra
dc.contributor.authorBilinski, Alyssa
dc.contributor.authorFitzpatrick, Meagan
dc.contributor.authorPaltiel, A David
dc.contributor.authorRizvi, Zain
dc.contributor.authorSalomon, Joshua
dc.contributor.authorThornhill, Thomas
dc.contributor.authorGonsalves, Gregg
dc.date.accessioned2022-09-21T12:03:11Z
dc.date.available2022-09-21T12:03:11Z
dc.date.issued2022-09-13
dc.identifier.urihttp://hdl.handle.net/10713/19823
dc.description.abstractObjectives: While almost 60% of the world has received at least one dose of COVID-19 vaccine, the global distribution of vaccination has not been equitable. Only 4% of the population of low-income countries (LICs) has received a full primary vaccine series, compared with over 70% of the population of high-income nations. Design: We used economic and epidemiological models, parameterised with public data on global vaccination and COVID-19 deaths, to estimate the potential benefits of scaling up vaccination programmes in LICs and lower-middle-income countries (LMICs) in 2022 in the context of global spread of the Omicron variant of SARS-CoV2. Setting: Low-income and lower-middle-income nations. Main outcome measures: Outcomes were expressed as number of avertable deaths through vaccination, costs of scale-up and cost per death averted. We conducted sensitivity analyses over a wide range of parameter estimates to account for uncertainty around key inputs. Findings: Globally, universal vaccination in LIC/LMIC with three doses of an mRNA vaccine would result in an estimated 1.5 million COVID-19 deaths averted with a total estimated cost of US$61 billion and an estimated cost-per-COVID-19 death averted of US$40 800 (sensitivity analysis range: US$7400-US$81 500). Lower estimated infection fatality ratios, higher cost-per-dose and lower vaccine effectiveness or uptake lead to higher cost-per-death averted estimates in the analysis. Conclusions: Scaling up COVID-19 global vaccination would avert millions of COVID-19 deaths and represents a reasonable investment in the context of the value of a statistical life. Given the magnitude of expected mortality facing LIC/LMIC without vaccination, this effort should be an urgent priority.en_US
dc.description.urihttps://doi:10.1136/bmjopen-2022-061752en_US
dc.language.isoenen_US
dc.relation.ispartofBMJ openen_US
dc.rights© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en_US
dc.subjectCOVID-19en_US
dc.subjectHEALTH ECONOMICSen_US
dc.subjectPublic healthen_US
dc.titleEstimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.en_US
dc.typeArticleen_US
dc.identifier.doi10.1136/bmjopen-2022-061752
dc.source.journaltitleBMJ open
dc.source.volume12
dc.source.issue9
dc.source.beginpagee061752
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record